← Browse by Condition
Medical Condition

dme

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT07449923 Phase 3
Recruiting

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Enrollment
240 pts
Location
United States
Sponsor
EyePoint Pharmaceuticals, Inc.
View Trial →